The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech ...

The clearance of Redemplo for a rare genetic disorder marks Arrowhead’s transition, after two decades, into a ...

Analysts say the two new indications should help Eylea HD as Regeneron battles for market share with Roche’s Vabysmo.

The deal gives J&J access to a pipeline of drugs designed to “hold and kill” tumors, led by a prostate cancer medicine that’s ...

With their promise to transform disease trajectories, cell and gene therapies (CGTs) are bringing new hope to patients with ...

Pyrukynd, which Agios sells for a rare type of anemia, missed one of its main objectives in a study seen as crucial for its ...

The new fund will mostly support biotechs making new drugs, with investments spanning from initial financings to follow-on ...

Now in a tug of war with Lundbeck, Alkermes could either lose out on a marketed sleepiness drug or end up paying ...

The purchase would give Abbott access to cancer screening tests including Cologuard and blood tests for multi-cancer early ...

After multiple clinical setbacks and layoff rounds, Mersana accepted an offer in which the bulk of the payouts will only ...

The alliance extends a deal streak in genetic medicine for Lilly and hands the company rights to an experimental treatment ...

The decision, issued without the input of an official advisory committee, revises long-held labeling on the drugs cautioning ...